Sarepta Therapeutics Inc
NASDAQ:SRPT

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
NASDAQ:SRPT
Watchlist
Price: 118.97 USD 0% Market Closed
Market Cap: 11.4B USD
Have any thoughts about
Sarepta Therapeutics Inc?
Write Note

Sarepta Therapeutics Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sarepta Therapeutics Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sarepta Therapeutics Inc
NASDAQ:SRPT
Cash & Cash Equivalents
$197.9m
CAGR 3-Years
-50%
CAGR 5-Years
-23%
CAGR 10-Years
14%
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%
No Stocks Found

Sarepta Therapeutics Inc
Glance View

Market Cap
11.4B USD
Industry
Biotechnology
Economic Moat
Narrow

Sarepta Therapeutics Inc. is a company firmly rooted in the ambitious quest to change the lives of those grappling with rare genetic disorders, particularly focusing on Duchenne muscular dystrophy (DMD). The scientists and innovators at Sarepta are driven by their expertise in genetic medicine, utilizing cutting-edge technologies such as exon skipping, gene therapy, and RNA-targeted therapeutics to develop treatments that combat the underlying causes of these debilitating diseases. The company's journey is underscored by its commitment to not only advancing science but also accelerating the delivery of hope to patients and families affected by these life-limiting conditions. Central to Sarepta's business model is the commercialization of its approved therapies, alongside an expansive pipeline of potential treatments still in various stages of research and development. By prioritizing strategic partnerships and leveraging their robust intellectual property portfolio, Sarepta translates pioneering science into tangible healthcare solutions. Revenue is chiefly generated through the sales of its FDA-approved DMD treatments, capturing a market niche due to the lack of viable alternatives. As Sarepta looks toward future horizons, the company remains steadfast in its mission to scale new heights in genetic medicine, aiming to redefine the standard of care for rare neuromuscular diseases worldwide.

SRPT Intrinsic Value
197.75 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Sarepta Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
197.9m USD

Based on the financial report for Sep 30, 2024, Sarepta Therapeutics Inc's Cash & Cash Equivalents amounts to 197.9m USD.

What is Sarepta Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%

Over the last year, the Cash & Cash Equivalents growth was -63%. The average annual Cash & Cash Equivalents growth rates for Sarepta Therapeutics Inc have been -50% over the past three years , -23% over the past five years , and 14% over the past ten years .

Back to Top